These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17941451)

  • 21. [Optimisation of treatment of Parkinson's disease with levodopa].
    Białecka M; Adamiak U; Gawrońska-Szklarz B
    Neurol Neurochir Pol; 2009; 43(5):446-59. PubMed ID: 20054747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopaminergic agonists in the treatment of Parkinson's disease: a review.
    Piccoli F; Riuggeri RM
    J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine receptors, motor responses, and dopaminergic agonists.
    Luquin-Piudo MR; Sanz P
    Neurologist; 2011 Nov; 17(6 Suppl 1):S2-8. PubMed ID: 22045321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Medicinal treatment of idiopathic Parkinson's disease].
    Klockgether T
    Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Arguments in favor of early treatment of Parkinson's disease with dopaminergic agonists].
    Rascol O
    Rev Neurol (Paris); 1999 Jan; 155(1):35-42. PubMed ID: 10093846
    [No Abstract]   [Full Text] [Related]  

  • 26. Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans.
    Wachtel H
    J Neural Transm Park Dis Dement Sect; 1991; 3(3):151-201. PubMed ID: 1683537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GSK's Requip slow the loss of dopamine function in Parkinson's disease.
    Aviat Space Environ Med; 2002 Jul; 73(7):733. PubMed ID: 12137117
    [No Abstract]   [Full Text] [Related]  

  • 28. Designing prodrugs for the treatment of Parkinson's disease.
    Sozio P; Cerasa LS; Abbadessa A; Di Stefano A
    Expert Opin Drug Discov; 2012 May; 7(5):385-406. PubMed ID: 22494466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drugs used to treat Parkinson's disease, present status and future directions.
    Abdel-Salam OM
    CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):321-42. PubMed ID: 18991661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The therapeutic plasma concentrations of antiparkinson dopamine agonists and their in vitro pharmacology at dopamine receptors].
    Tadori Y; Kobayashi H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2014 Nov; 34(5-6):127-32. PubMed ID: 25536763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are All Dopamine Agonists Essentially the Same?
    Torti M; Bravi D; Vacca L; Stocchi F
    Drugs; 2019 May; 79(7):693-703. PubMed ID: 30968290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine agonists, sleep disorders, and driving in Parkinson's disease.
    Uitti RJ; Wszolek ZK
    Adv Neurol; 2003; 91():343-9. PubMed ID: 12442692
    [No Abstract]   [Full Text] [Related]  

  • 33. [Adverse effects of dopamine agonists].
    Fiszer U
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S34-9. PubMed ID: 17941457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The pharmacological and rational theory for the drug development of Parkinson's disease].
    Nomoto M
    Nihon Rinsho; 2004 Sep; 62(9):1653-60. PubMed ID: 15462380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of dopamine agonists in Parkinson's disease: an update.
    Bonuccelli U; Pavese N
    Expert Rev Neurother; 2007 Oct; 7(10):1391-9. PubMed ID: 17939774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiparkinson prodrugs.
    Di Stefano A; Sozio P; Cerasa LS
    Molecules; 2008 Jan; 13(1):46-68. PubMed ID: 18259129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent advances in pharmacological therapy of Parkinson's disease.
    Riederer P; Lange KW; Youdim MB
    Adv Neurol; 1993; 60():626-35. PubMed ID: 8093582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
    Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
    J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The role of estrogens in Parkinson's disease].
    Dziedziejko V; Białecka M; Machoy-Mokrzyńska A; Kłodowska-Duda G; Chlubek D
    Postepy Hig Med Dosw (Online); 2009 Dec; 63():627-33. PubMed ID: 20097949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.